Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS

@article{Methner2013MultipleSI,
  title={Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS},
  author={Axel Methner and Frauke Zipp},
  journal={Nature Reviews Neurology},
  year={2013},
  volume={9},
  pages={72-73}
}
2012 witnessed important developments for multiple sclerosis, including successful phase III trials of novel oral therapeutics and identification of the potassium channel KIR4.1 as an autoimmune target. Additionally, the lung was highlighted as an important site for immune-cell programming, and the relevance of a TNF receptor variant was clarified. 
Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS
TLDR
This work aims to provide a clear picture of the role of dopamine in the development of central nervous system injury and the use of drugs to treat these injuries is a natural application.
A clinical conundrum: the detrimental effect of TNF antagonists in multiple sclerosis.
TLDR
It is shown that genetic risk drives the production of a novel, endogenous TNF antagonist, which mirrors the clinical experience with the drugs and indicates that the net effect of TNF function in MS development is a protective one, warranting a re-evaluation of the studies that have contributed to understanding TNF signaling in inflammation, immunoregulation and neuroprotection.
Protease activated receptor‐1 antagonist ameliorates the clinical symptoms of experimental autoimmune encephalomyelitis via inhibiting breakdown of blood–brain barrier
TLDR
The results suggest that PAR‐1 antagonist is effective in attenuation of the clinical symptoms of EAE mice by stabilizing the blood–brain barrier and may have therapeutic potential for treatment of multiple sclerosis.
Thiamine Deficiency Promotes T Cell Infiltration in Experimental Autoimmune Encephalomyelitis: The Involvement of CCL2
TLDR
The results suggested that TD exacerbated the development of EAE through activating CCL2 and inducing pathologic inflammation.
Thiamine Deficiency Promotes T Cell Infiltration in Experimental Autoimmune Encephalomyelitis: The Involvement of CCL2
TLDR
The results suggested that TD exacerbated the development of EAE through activating CCL2 and inducing pathologic inflammation.
Chapter 30 – Multiple Sclerosis
TLDR
One of the major challenges in MS research is to find therapies to prevent the permanent and irreversible neurological decline characterizing the chronic progressive phase of the disease, and to restore function.
Clozapine reduces infiltration into the CNS by targeting migration in experimental autoimmune encephalomyelitis
TLDR
This study indicates that clozapine protects against EAE by two different mechanisms; first, by reducing the chemoattractant proteins in the CNS; and second, by direct targeting the migration potential of peripheral immune cells.
Multiple sclerosis: New insights and trends
TLDR
MS is an autoimmune disease affecting principally the central nervous system that cause nerve sheath demyelination followed by axon damage and paralysis, and symptoms include muscle weakness, weak reflexes, muscle spasm, difficult in move, miss-coordination and unbalance with others.
LncRNA GAS5 and miR-137 polymorphisms and expression are associated with multiple sclerosis risk: mechanistic insights and potential clinical impact.
TLDR
Serum GAS5 and miR-137 and rs2067079 and rs1625579 are proposed as novel genetic markers of MS susceptibility, at least rs 2067079 possibly impacts the crosstalk between GAS4 and miRs137, and GAS 5 as a marker of MS severity.
Lipid‐specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
TLDR
This work explored whether the presence of lipid‐specific immunoglobulin M oligoclonal bands in cerebrospinal fluid (CSF; IgM bands), a recognized marker of highly inflammatory MS, may identify individuals better able to counteract the potential immunosuppressive effect of natalizumab and hence be associated with a reduced risk of developing PML.
...
1
2
...

References

SHOWING 1-10 OF 11 REFERENCES
Potassium channel KIR4.1 as an immune target in multiple sclerosis.
TLDR
KIR4.1 is a target of the autoantibody response in a subgroup of persons with multiple sclerosis and shown its potential pathogenicity in vivo.
Insight into the mechanism of laquinimod action
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
TLDR
In patients with relapsing-remitting multiple sclerosis, both BG-12 regimens, as compared with placebo, significantly reduced the proportion of patients who had a relapse, the annualized relapse rate, the rate of disability progression, and the number of lesions on MRI.
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis
TLDR
This study demonstrates that clinical practice can be informed by comparing GWAS across common autoimmune diseases and by investigating the functional consequences of the disease-associated genetic variation.
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.
TLDR
The ability of dimethylfumarate to activate nuclear factor (erythroid-derived 2)-related factor 2 may offer a novel cytoprotective modality that further augments the natural antioxidant responses in multiple sclerosis tissue and is not yet targeted by other multiple sclerosis therapies.
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
TLDR
In this phase 3 study, oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing-remitting multiple sclerosis.
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity
TLDR
Oral laquinimod treatment reversed established RR-EAE and was associated with reduced central nervous system (CNS) inflammation, decreased Th1 and Th17 responses, and an increase in regulatory T cells (Treg).
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
TLDR
In patients with relapsing-remitting multiple sclerosis, BG-12 (at both doses) and glatiramer acetate significantly reduced relapse rates and improved neuroradiologic outcomes relative to placebo.
Effects of dimethyl fumarate on neuroprotection and immunomodulation
TLDR
These results suggest that immunomodulatory concentrations of dimethyl fumarate can reduce oxidative stress without altering neuronal network activity.
T cells become licensed in the lung to enter the central nervous system
TLDR
It is detected that the lung constitutes a niche not only for activated T cells but also for resting myelin-reactive memory T cells, which could contribute to the activation of potentially autoaggressive T cells and their transition to a migratory mode as a prerequisite to entering their target tissues and inducing autoimmune disease.
...
1
2
...